Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.